Equine immunoglobulin fragment F(ab')2 displays high neutralizing capability against multiple SARS-CoV-2 variants

Equine immunoglobulin fragment F(ab')2 displays high neutralizing capability against multiple SARS-CoV-2 variants

Copyright © 2022 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 237(2022) vom: 15. Apr., Seite 108981
1. Verfasser: Gupta, Divya (VerfasserIn)
Weitere Verfasser: Ahmed, Farhan, Tandel, Dixit, Parthasarathy, Haripriya, Vedagiri, Dhiviya, Sah, Vishal, Krishna Mohan, B, Khan, Rafiq Ahmad, Kondiparthi, Chiranjeevi, Savari, Prabhudas, Jain, Sandesh, Reddy, Shashikala, Kumar, Jerald Mahesh, Khan, Nooruddin, Harshan, Krishnan Harinivas
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Antisera COVID-19 F(ab’)(2) Passive immunotherapy SARS-CoV-2 Virus neutralization Antibodies, Neutralizing Antibodies, Viral mehr... Immunoglobulin Fab Fragments Immunoglobulin Fragments
Beschreibung
Zusammenfassung:Copyright © 2022 Elsevier Inc. All rights reserved.
Neutralizing antibody-based passive immunotherapy could be an important therapeutic option against COVID-19. Herein, we demonstrate that equines hyper-immunized with chemically inactivated SARS-CoV-2 elicited high antibody titers with a strong virus-neutralizing potential, and F(ab')2 fragments purified from them displayed strong neutralization potential against five different SARS-CoV-2 variants. F(ab')2 fragments purified from the plasma of hyperimmunized horses showed high antigen-specific affinity. Experiments in rabbits suggested that the F(ab')2 displays a linear pharmacokinetics with approximate plasma half-life of 47 h. In vitro microneutralization assays using the purified F(ab')2 displayed high neutralization titers against five different variants of SARS-CoV-2 including the Delta variant, demonstrating its potential efficacy against the emerging viral variants. In conclusion, this study demonstrates that F(ab')2 generated against SARS-CoV-2 in equines have high neutralization titers and have broad target-range against the evolving variants, making passive immunotherapy a potential regimen against the existing and evolving SARS-CoV-2 variants in combating COVID-19
Beschreibung:Date Completed 18.04.2022
Date Revised 03.01.2023
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2022.108981